Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides

Cardiovascular disease (CVD) remains the leading cause of mortality in westernized countries, despite optimum medical therapy to lower LDL cholesterol. The pursuit of novel therapies to target this residual risk has focused on raising levels of HDL cholesterol in order to exploit its atheroprotectiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rayner, Katey J., Esau, Christine C., Hussain, Farah N., McDaniel, Allison L., Marshall, Stephanie M., van Gils, Janine M., Ray, Tathagat D., Sheedy, Frederick J., Goedeke, Leigh, Liu, Xueqing, Khatsenko, Oleg G., Kaimal, Vivek, Lees, Cynthia J., Fernandez-Hernando, Carlos, Fisher, Edward A., Temel, Ryan E., Moore, Kathryn J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3235584/
https://ncbi.nlm.nih.gov/pubmed/22012398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature10486
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados